Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) - Pipeline Review, H2 2016

Publisher Name :
Date: 14-Sep-2016
No. of pages: 221

Note*:

*Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Global Markets Direct's, ‘Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) - Pipeline Review, H2 2016', provides in depth analysis on Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) targeted pipeline therapeutics.

The report provides comprehensive information on the Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1)

  • The report reviews Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

  • The report reviews key players involved in Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) targeted therapeutics and enlists all their major and minor projects

  • The report assesses Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

  • The report summarizes all the dormant and discontinued pipeline projects

  • The report reviews latest news and deals related to Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

  • Identify and understand the targeted therapy areas and indications for Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1)

  • Identify the use of drugs for target identification and drug repurposing

  • Identify potential new clients or partners in the target demographic

  • Develop strategic initiatives by understanding the focus areas of leading companies

  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

  • Devise corrective measures for pipeline projects by understanding Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) development landscape

  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) - Pipeline Review, H2 2016

Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) Overview 8
Therapeutics Development 9
Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) - Products under Development by Stage of Development 9
Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) - Products under Development by Therapy Area 10
Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) - Products under Development by Indication 11
Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) - Pipeline Products Glance 15
Late Stage Products 15
Early Stage Products 16
Unknown Stage Products 17
Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) - Products under Development by Companies 18
Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) - Products under Development by Universities/Institutes 34
Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) - Therapeutics Assessment 36
Assessment by Monotherapy/Combination Products 36
Assessment by Mechanism of Action 37
Assessment by Route of Administration 39
Assessment by Molecule Type 41
Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) - Companies Involved in Therapeutics Development 43
Aduro BioTech, Inc. 43
Agenus, Inc. 44
Aurigene Discovery Technologies Limited 45
BeiGene, Ltd. 46
Beijing Hanmi Pharmaceutical Co., Ltd. 47
BIOCAD 48
Cellular Biomedicine Group, Inc. 49
CytomX Therapeutics, Inc. 50
Eli Lilly and Company 51
Enumeral Biomedical Holdings, Inc. 52
Immunovo BV 53
Jiangsu Hengrui Medicine Co., Ltd. 54
Jounce Therapeutics, Inc. 55
Les Laboratoires Servier SAS 56
MacroGenics, Inc. 57
MD Biosciences GmbH 58
MedImmune, LLC 59
Merck & Co., Inc. 60
Molecular Partners AG 62
Novartis AG 63
Ono Pharmaceutical Co., Ltd. 64
Pfizer Inc. 68
PharmaEssentia Corporation 69
Pieris Pharmaceuticals Inc 70
Regeneron Pharmaceuticals Inc 71
Sutro Biopharma, Inc. 72
Symphogen A/S 73
Tasly Pharmaceutical Group Co., Ltd. 74
Tesaro, Inc. 75
Theravectys SA 76
Tikcro Technologies, Ltd. 77
Vyriad 78
Xencor, Inc. 79
Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) - Drug Profiles 80
AM-0001 - Drug Profile 80
AMP-224 - Drug Profile 81
Anti-PD1 Monoclonal Antibody + Cellular Immunotherapy for Glioblastoma - Drug Profile 83
AUR-012 - Drug Profile 84
BGB-108 - Drug Profile 85
BGBA-317 - Drug Profile 86
Biologic to Antagonize CTLA4 and PD-1 for Solid Tumor - Drug Profile 87
Drug to Inhibit PD-1, Gal-9 and TIM-3 for Solid Tumor - Drug Profile 88
durvalumab + MEDI-0680 - Drug Profile 89
ENUM-003 - Drug Profile 90
ENUM-388D4 - Drug Profile 92
GXP-2 - Drug Profile 93
IBI-308 - Drug Profile 94
JS-001 - Drug Profile 95
MD-402 - Drug Profile 96
mDX-400 - Drug Profile 97
MEDI-0680 - Drug Profile 98
MGD-013 - Drug Profile 99
Monoclonal Antibodies to Antagonize PD-1 for Oncology - Drug Profile 100
Monoclonal Antibodies to Antagonize PD-1 for Oncology - Drug Profile 101
Monoclonal Antibodies to Antagonize PD1 for Metastatic Melanoma and Metastatic Lung Cancer - Drug Profile 102
Monoclonal Antibodies to Inhibit CTLA4 and PD-1 for Oncology - Drug Profile 103
Monoclonal Antibodies to Inhibit PD-1/PD-L1 for Hematological Malignancies and Bacterial Infections - Drug Profile 104
Monoclonal Antibody to Antagonize PD-1 for Autoimmune Disorders and Oncology - Drug Profile 105
Monoclonal Antibody to Antagonize PD-1 for Non-Small Cell Lung Cancer - Drug Profile 106
Monoclonal Antibody to Antagonize PD-1 for Oncology - Drug Profile 107
Monoclonal Antibody to Antagonize PD-1 for Oncology - Drug Profile 108
Monoclonal Antibody to Antagonize PD-1 for Oncology - Drug Profile 109
Monoclonal Antibody to Antagonize PD1 for Oncology - Drug Profile 110
Monoclonal Antibody to Antagonize PD1 for Oncology - Drug Profile 111
Monoclonal Antibody to Inhibit PD-1 and LAG3 for Oncology - Drug Profile 112
Monoclonal Antibody to Inhibit PD-1 and TIM3 for Oncology - Drug Profile 113
Monoclonal Antibody to Inhibit PD-1 for Cancer - Drug Profile 114
Monoclonal Antibody to Inhibit PD-1 for HIV - Drug Profile 115
Monoclonal Antibody to Inhibit PD-1 for Oncology - Drug Profile 116
Monocloncal Antibody to Inhibit PD-1 for Oncology - Drug Profile 117
nivolumab - Drug Profile 118
Oncolytic Virus to Activate IFNb for Head and Neck Cancer and Lewis Lung Cancer - Drug Profile 148
pazopanib hydrochloride + pembrolizumab - Drug Profile 149
PD-1 Antagonist + ropeginterferon alfa-2b - Drug Profile 150
PDR-001 - Drug Profile 151
PEGMP-7 - Drug Profile 152
pembrolizumab - Drug Profile 153
PF-06801591 - Drug Profile 185
PRS-332 - Drug Profile 186
Recombinant Protein to Inhibit VEGF-A and PD1 for Solid Tumor and Hematological Malignancies - Drug Profile 187
REGN-2810 - Drug Profile 188
SHR-1210 - Drug Profile 190
SNPD-07 - Drug Profile 191
STIA-1110 - Drug Profile 192
TSR-042 - Drug Profile 193
Vaccine to Target CD274 and CD279 for Bladder Cancer - Drug Profile 194
Vaccine to Target CD274 and CD279 for Colorectal Cancer - Drug Profile 195
Vaccine to Target CD274 and CD279 for Renal Cell Carcinoma - Drug Profile 196
XmAb-20717 - Drug Profile 197
Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) - Dormant Projects 198
Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) - Discontinued Products 199
Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) - Featured News & Press Releases 200
Appendix 216
Methodology 216
Coverage 216
Secondary Research 216
Primary Research 216
Expert Panel Validation 216
Contact Us 216
Disclaimer 217

List of Tables

Number of Products under Development for, H2 2016 13
Number of Products under Development by Therapy Area, H2 2016 14
Number of Products under Development by Indication, H2 2016 15
Comparative Analysis by Late Stage Development, H2 2016 19
Comparative Analysis by Early Stage Products, H2 2016 20
Comparative Analysis by Unknown Stage Development, H2 2016 21
Number of Products under Development by Companies, H2 2016 22
Number of Products under Development by Companies, H2 2016 (Contd..1) 23
Products under Development by Companies, H2 2016 24
Products under Development by Companies, H2 2016 (Contd..1) 25
Products under Development by Companies, H2 2016 (Contd..2) 26
Products under Development by Companies, H2 2016 (Contd..3) 27
Products under Development by Companies, H2 2016 (Contd..4) 28
Products under Development by Companies, H2 2016 (Contd..5) 29
Products under Development by Companies, H2 2016 (Contd..6) 30
Products under Development by Companies, H2 2016 (Contd..7) 31
Products under Development by Companies, H2 2016 (Contd..8) 32
Products under Development by Companies, H2 2016 (Contd..9) 33
Products under Development by Companies, H2 2016 (Contd..10) 34
Products under Development by Companies, H2 2016 (Contd..11) 35
Products under Development by Companies, H2 2016 (Contd..12) 36
Products under Development by Companies, H2 2016 (Contd..13) 37
Number of Products under Investigation by Universities/Institutes, H2 2016 38
Products under Investigation by Universities/Institutes, H2 2016 39
Assessment by Monotherapy/Combination Products, H2 2016 40
Number of Products by Stage and Mechanism of Action, H2 2016 42
Number of Products by Stage and Route of Administration, H2 2016 44
Number of Products by Stage and Molecule Type, H2 2016 46
Pipeline by Aduro BioTech, Inc., H2 2016 47
Pipeline by Agenus, Inc., H2 2016 48
Pipeline by Aurigene Discovery Technologies Limited, H2 2016 49
Pipeline by BeiGene, Ltd., H2 2016 50
Pipeline by Beijing Hanmi Pharmaceutical Co., Ltd., H2 2016 51
Pipeline by BIOCAD, H2 2016 52
Pipeline by Cellular Biomedicine Group, Inc., H2 2016 53
Pipeline by CytomX Therapeutics, Inc., H2 2016 54
Pipeline by Eli Lilly and Company, H2 2016 55
Pipeline by Enumeral Biomedical Holdings, Inc., H2 2016 56
Pipeline by Immunovo BV, H2 2016 57
Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H2 2016 58
Pipeline by Jounce Therapeutics, Inc., H2 2016 59
Pipeline by Les Laboratoires Servier SAS, H2 2016 60
Pipeline by MacroGenics, Inc., H2 2016 61
Pipeline by MD Biosciences GmbH, H2 2016 62
Pipeline by MedImmune, LLC, H2 2016 63
Pipeline by Merck & Co., Inc., H2 2016 64
Pipeline by Molecular Partners AG, H2 2016 66
Pipeline by Novartis AG, H2 2016 67
Pipeline by Ono Pharmaceutical Co., Ltd., H2 2016 68
Pipeline by Pfizer Inc., H2 2016 72
Pipeline by PharmaEssentia Corporation, H2 2016 73
Pipeline by Pieris Pharmaceuticals Inc, H2 2016 74
Pipeline by Regeneron Pharmaceuticals Inc, H2 2016 75
Pipeline by Sutro Biopharma, Inc., H2 2016 76
Pipeline by Symphogen A/S, H2 2016 77
Pipeline by Tasly Pharmaceutical Group Co., Ltd., H2 2016 78
Pipeline by Tesaro, Inc., H2 2016 79
Pipeline by Theravectys SA, H2 2016 80
Pipeline by Tikcro Technologies, Ltd., H2 2016 81
Pipeline by Vyriad, H2 2016 82
Pipeline by Xencor, Inc., H2 2016 83
Dormant Projects, H2 2016 202
Discontinued Products, H2 2016 203

List of Figures

Number of Products under Development for, H2 2016 13
Number of Products under Development by Therapy Area, H2 2016 14
Number of Products under Development by Indication, H2 2016 15
Comparative Analysis by Late Stage Development, H2 2016 19
Comparative Analysis by Early Stage Products, H2 2016 20
Assessment by Monotherapy/Combination Products, H2 2016 40
Number of Products by Mechanism of Actions, H2 2016 41
Number of Products by Stage and Mechanism of Actions, H2 2016 41
Number of Products by Routes of Administration, H2 2016 43
Number of Products by Stage and Routes of Administration, H2 2016 43
Number of Products by Molecule Types, H2 2016 45
Number of Products by Stage and Molecule Type, H2 2016 45
  • Global Luxury Apparels Market To Do Well Owing To Numerous International Brands
    The global luxury apparels market is fired by the intensifying number of fashion marques and many designers getting wide-ranging clienteles in the form of cost-effective products. The global luxury apparels market was at US$1, 8842.69 million in 2015 and is forecast to reach US$60,793.7 million by the end of 2024. This segment of luxury goods [...]
  • Global Health and Wellness Market Boosted By Organic Products and Wearables
    Healthcare has constantly been a profitable area where buyers spend belligerently. But now, with increasing disposable earnings amid the city population and ground-breaking approaches and innovative products being developed, the overall health and wellness market is estimated for a healthy prospect. The health and wellness market is presently very dynamic owing to growing alertness amongst [...]
  • Increasing New Outlets And Striking Offers To Drive Global Pizza Market
    The global pizza market is predicted to grow at a steady CAGR of about 3% by 2020. Pizza has been gaining massive acceptance globally in the last few years. Consequently, the global pizza market is anticipated to observer considerable progress in the coming years. The growing number of pizzerias is one of the major elements [...]
  • Healthy Diet Demand In Developed Economies To Boost Nutraceuticals
    As customers scuffle to keep up with the frantic lifestyles, the necessity for healthy nutrition rises owing to dearth of time to spend on laborious exercises.  Customers are shifting their attention to swift and healthy food behaviours. Increase in intake of beverages and functional food has offered makers of nutraceuticals with money-spinning prospects to benefit [...]
  • World Economic Forum Unveils Top 10 Emerging Technologies of 2016
    The World Economic Forum (WEF) and Scientific American lately unveiled the major technological innovation list of the top ten emerging technologies of 2016. This list emphasizes on the technological developments which have the supremacy to transform industries, protect the planet, and improve lives. It also presents an opening to discuss any societal, human, economic or [...]
  • United States Medical Swab Market Report 2016
    Published: 29-Nov-2016        Price: US 3800 Onwards        Pages: 102
    Notes: Sales, means the sales volume of Medical Swab Revenue, means the sales value of Medical Swab This report studies sales (consumption) of Medical Swab in United States market, focuses on the top players, with sales, price, revenue and market share for each player, covering - Medical Wire & Equipment - Puritan Medical Products - F.L. Medical - Copan Split by product types, with sales, revenue, price, market share and gro......
  • Global Cell Counting Sales Market Report 2016
    Published: 29-Nov-2016        Price: US 4000 Onwards        Pages: 120
    Notes: Sales, means the sales volume of Cell Counting Revenue, means the sales value of Cell Counting This report studies sales (consumption) of Cell Counting in Global market, especially in USA, China, Europe, Japan, India and Southeast Asia, focuses on top players in these regions/countries, with sales, price, revenue and market share for each player in these regions, covering - Thermo Fisher Scientific - Merck - BD - Bio-Rad - Pe......
  • Immunohistochemistry Market by Product (Antibody, Reagent, Kits, Slide Staining System, Tissue Microarray) Application (Diagnostics (Cancer, Cardiovascular, Diabetes, Autoimmune, Infectious Diseases) & Drug Testing) End User - Global Forecast to 2021
    Published: 29-Nov-2016        Price: US 5650 Onwards        Pages: 225
    The immunohistochemistry (IHC) market is projected to reach USD 2.12 Billion by 2021, growing at a CAGR of 7.3% during the forecast period of 2016 to 2021. Factors such as the growing prevalence of cancer and rapidly increasing geriatric population across the globe are the primary driving the growth of this market. Other factors driving the IHC market growth include increasing healthcare spending and improving healthcare infrastructure resulting in an increasing number of hospitals and diagno......
  • Global Expression Vectors Sales Market Report 2016
    Published: 29-Nov-2016        Price: US 4000 Onwards        Pages: 121
    Notes: Sales, means the sales volume of Expression Vectors Revenue, means the sales value of Expression Vectors This report studies sales (consumption) of Expression Vectors in Global market, especially in USA, China, Europe, Japan, India and Southeast Asia, focuses on top players in these regions/countries, with sales, price, revenue and market share for each player in these regions, covering - Merck - Thermo Fisher Scientific - Agilent Technolo......
  • Global Molecular Biology Kits Sales Market Report 2016
    Published: 29-Nov-2016        Price: US 4000 Onwards        Pages: 123
    Notes: Sales, means the sales volume of Molecular Biology Kits Revenue, means the sales value of Molecular Biology Kits This report studies sales (consumption) of Molecular Biology Kits in Global market, especially in USA, China, Europe, Japan, India and Southeast Asia, focuses on top players in these regions/countries, with sales, price, revenue and market share for each player in these regions, covering - QIAGEN - Agilent Technologies - Merck......
  • Global Biotechnology Separation Systems Market by Manufacturers, Regions, Type and Application, Forecast to 2021
    Published: 28-Nov-2016        Price: US 3480 Onwards        Pages: 113
    The global market is further analyzed by the following types: DNA microarray, flow cytometry, liquid chromatography, membrane filtration, protein microarray, and others.This report analyzes the worldwide markets for biotechnology separation systems in us$.Scope of the Report:This report focuses on the Biotechnology Separation Systems in Global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the......
  • Europe Biotech API Market Report 2016
    Published: 28-Nov-2016        Price: US 3900 Onwards        Pages: 125
    Notes: Sales, means the sales volume of Biotech API Revenue, means the sales value of Biotech API This report studies sales (consumption) of Biotech API in Europe market, especially in Germany, UK, France, Russia, Italy, Benelux and Spain, focuses on top players in these countries, with sales, price, revenue and market share for each player in these Countries, covering - Teva Active Pharmaceutical Industries Limited - DSM - Novartis - Roch......
  • High-Throughput Screening Market by Technology (Cell-based Assays (2D & 3D Cell Culture), Lab-on-a-chip, Bioinformatics), Application (Target Identification, Primary Screening, Toxicology), Product (Reagent & Instruments), End User - Forecast to 2021
    Published: 24-Nov-2016        Price: US 5650 Onwards        Pages: 252
    The high-throughput screening (HTS) market is expected to grow at a lucrative CAGR of 7.8% from 2016 to 2021, to reach USD 18.83 billion by 2021 from USD 12.23 billion in 2016. Market growth can be attributed to the growing adoption of open innovative models in the pharmaceutical and biotechnology industry and technological advancements like automation and miniaturization, increasing R&D spending and rising government funding. Emerging markets and growing research activities in to......
  • Global Protein Crystallization and Crystallography Market by Manufacturers, Regions, Type and Application, Forecast to 2021
    Published: 23-Nov-2016        Price: US 3480 Onwards        Pages: 113
    Protein crystallization is the process of formation of a protein crystal. These crystals can then be used in structural biology to study the molecular structure of the protein. Protein crystallography is used to determine the structure of proteins. Cryo-electron microscopy (cryo-EM) is a form of transmission electron microscopy (TEM) where the sample is studied at cryogenic temperatures. Protein molecular structure can also be obtained through Cryo-EM.Statistics for this report include reagen......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs